Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Financings Routine +

Optimi Health closes $15-million (U.S.) public offering

Optimi Health Secures Nasdaq Listing and $15M Runway Amidst Dilution Concerns

By The Northwire Desk — AI Analysis May 21, 2026 · 19:15 OPTI · 7.84 Optimi Health Corp
Executive Summary
  • Optimi Health Corp. has successfully closed a US$15 million public offering, issuing 2.4 million common shares at $6.25 USD per share.
  • The company completed its uplisting to the Nasdaq Capital Market under the ticker symbol OPTH on May 20, 2026.
  • Trading continues on the Canadian Securities Exchange (CSE) under OPTI following a 1-for-30 reverse stock consolidation effective May 19, 2026.
  • Proceeds are designated for strengthening the balance sheet, working capital, and scaling production/distribution in current markets including the US expansion.
  • The offering was oversubscribed, with Joseph Gunnar & Co., LLC acting as sole book-running manager.
  • Underwriter received 96,000 warrants at $7.50 USD per share expiring May 21, 2031.
Material Impact
  • Capital Injection: The US$15 million raise provides significant runway for operations, reducing immediate liquidity risk and allowing for the scaling of GMP manufacturing capabilities.
  • Listing Milestone: Uplisting to Nasdaq improves visibility, liquidity, and access to institutional investors compared to CSE, which is a structural positive for long-term valuation.
  • Dilution Risk: The offering price ($6.25) was significantly below the pre-offer market price (~$9.75 on May 19), indicating discount pricing that dilutes existing shareholders and creates immediate downward pressure on stock value.
  • Market Reaction: Stock price declined from $9.75 to $8.20 immediately post-closing, settling at $7.84 by the close of news release, reflecting market absorption of the dilution despite oversubscription.
  • Strategic Alignment: The financing supports the previously announced Ibogaine Initiative and US expansion plans, aligning capital with strategic growth rather than just survival.
OPTI · Price
Company Overview
  • Core Business: GMP-compliant manufacturing and supply of psychedelic medicines (MDMA, Psilocybin) for clinical trials and regulated therapeutic use.
  • Flagship Projects:
    • Australia Program: Supplying MDMA capsules for PTSD treatment and Psilocybin capsules for Treatment-Resistant Depression under the Authorised Prescriber Scheme.
    • Ibogaine Initiative: New program to manufacture ibogaine in response to US Executive Order, targeting opioid withdrawal and PTSD markets.
    • Israel Trial: Exclusive supplier for MAPS Israel's clinical trial on trauma-related PTSD.
  • Manufacturing: Two 10,000-square-foot GMP facilities in British Columbia licensed by Health Canada.
Read the original news release →

More from Optimi Health Corp

Jun 29, 2026 · 09:00

Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression

Production / Operations Jun 16, 2026 · 08:30

Vertically integrated GMP psychedelic manufacturer scaling clinical supply, but revenue remains negligible and execution is incremental.

Production / Operations Jun 10, 2026 · 09:15

Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial

Production / Operations Jun 08, 2026 · 08:00

Psychedelic GMP manufacturer advances ibogaine development amid US policy tailwinds, but commercial revenue remains negligible.

Regulatory Jun 02, 2026 · 07:30

Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia

Production / Operations May 29, 2026 · 08:30

Australia widens insurance-backed psychedelic therapy access — Optimi’s existing supply chain gains yet another tailwind, but market still awaits proof-of-revenue.

Regulatory